Trial
NCT06146374
Safety Study of SLV213 for the Treatment of COVID-19.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
COVID-19
Intervention
Placebo for SLV213
Why stopped
DMID unanimously arrived at a recommendation to terminate the study after study met cohort halting criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-22